Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 5/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8312964 | 1.00 | PARP15 (0.54) | PARP15PARP10PARP2HPGDALDH1A1 | |
| SCHEMBL8314306 | 1.00 | PARP15 (0.54) | PARP15PARP10PARP2HPGDALDH1A1 | |
| SCHEMBL22820830 | 0.95 | PARP15 (0.50) | PARP15PARP10PARP2HPGDALDH1A1 | |
| SCHEMBL6686905 | 0.94 | PARP15 (0.58) | PARP15PARP10PARP2HPGDALDH1A1 | |
| SCHEMBL1299143 | 0.93 | HPGD (0.58) | PARP15PARP10PARP2HPGDALDH1A1 | |
| SCHEMBL1299517 | 0.92 | HPGD (0.61) | PARP15PARP10PARP2HPGDALDH1A1 | |
| SCHEMBL1299658 | 0.91 | HPGD (0.59) | PARP15PARP10PARP2HPGDALDH1A1 | |
| SCHEMBL10906512 | 0.91 | HPGD (0.59) | PARP15PARP10PARP2HPGDALDH1A1 | |
| SCHEMBL3067625 | 0.90 | PARP15 (0.54) | PARP15PARP10PARP2HPGDALDH1A1 | |
| SCHEMBL28371333 | 0.88 | ALDH1A1 (0.50) | PARP15PARP10PARP2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035361-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | SHANGHAI DEGRON BIOMEDICAL TECH CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| US-12528773-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2026-01-20 | — | — | US | disclosed |
| EP-4626880-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | Shanghai Degron Biomedical Technology Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| EP-4622647-A1 | RNA DEGRADERS AND USES THEREOF | Arrakis Therapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-4021901-B1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20240400563-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-05 | — | — | US | disclosed |
| WO-2024114639-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | SHANGHAI DEGRON BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2024-06-06 | — | — | WO | disclosed |
| CN-114302884-B | Substituted pyridopyrimidinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2024112918-A1 | RNA DEGRADERS AND USES THEREOF | ARRAKIS THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| CN-112654621-B | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-2881384-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-06-10 | — | — | EP | disclosed |
| CN-104507910-A | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO LTD | 2015-04-08 | — | — | CN | disclosed |
| CN-102015715-A | Fused pyrimidones as TRPV3 modulators | GLENMARK PHARMACEUTICALS SA | 2011-04-13 | — | — | CN | disclosed |
| WO-2010127212-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280067-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE | SARMA PAKALA KUMARA SAVITHRU | 2010-11-04 | — | — | US | disclosed |
| US-20090221649-A1 | Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion injury and reperfusion damage | BAYER HEALTHCARE AG (DE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221649-A1 | Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion injury and reperfusion damage | BAYER HEALTHCARE AG (DE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221649-A1 | Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion injury and reperfusion damage | BAYER HEALTHCARE AG (DE) | 2009-09-03 | — | — | US | disclosed |
| EP-1863482-A1 | USE OF SUBSTITUTED 2-THIO-3,5-DICYANO-4-PHENYL-6-AMINOPYRIDINES FOR THE TREATMENT OF REPERFUSION INJURY AND REPERFUSION DAMAGE | Bayer HealthCare AG (DE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006099958-A1 | USE OF SUBSTITUTED 2-THIO-3,5-DICYANO-4-PHENYL-6-AMINOPYRIDINES FOR THE TREATMENT OF REPERFUSION INJURY AND REPERFUSION DAMAGE | BAYER HEALTHCARE AG (DE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528773-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, GAA | PARP15 4010/4885PARP10 3942/4885PARP2 4231/4885 |
| US-20240400563-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | PARP15 1689/4885PARP10 1518/4885PARP2 2439/4885 |
| US-20090221649-A1 | Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion injury and reperfusion damage | TNNI3, CASP3, GOT2 | PARP15 1341/4885PARP10 2576/4885PARP2 905/4885 |
| US-20100280067-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE | ACACA, ACACB, PC | PARP15 419/4885PARP10 607/4885PARP2 643/4885 |
| US-20260035361-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | ELAVL1, ELAVL3, HNRNPL | PARP15 3662/4885PARP10 3592/4885PARP2 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.